Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence

Semaglutide significantly improves glycemic control and promotes weight and BMI reduction in T2DM patients in routine clinical practice. These findings suggest that structured follow-up under endocrinologist supervision, as required by national protocols, may enhance therapeutic response. Further prospective studies with extended follow-up are warranted to evaluate the long-term sustainability of these effects and to identify predictors of optimal patient response.